(VIANEWS) – Today, the Innrs artificial intelligence algorithm suggests a high probability of discovering the approximate price for tomorrow of GlaxoSmithKline GSK, Visa V and others.
Via News will regularly fact-check this AI algorithm that aims to consistently predict the next session price and next week’s trend of financial assets.
Innrs provides A.I.-based statistical tools to help investors make decisions. The table below shows the financial assets predicting price, ordered by the highest expected accuracy.
Innrs officials say this tool helps investors make better-informed decisions, supposedly used alongside other relevant financial information and the specific trader strategy.
In the next session, Via News will report the finding on the algorithm precision.
| Financial Asset | Accuracy | Close Price | Prediction |
|---|---|---|---|
| GlaxoSmithKline (GSK) | 93.89% | $35.12 | ⇧ $35.91 |
| Visa (V) | 93.64% | $219.84 | ⇧ $223.58 |
| Hasbro (HAS) | 93.63% | $50.42 | ⇧ $51.67 |
| Match Group (MTCH) | 93.32% | $39.49 | ⇧ $40.63 |
| General Motors (GM) | 93.18% | $34.18 | ⇧ $34.45 |
| Honda (HMC) | 89.47% | $25.85 | ⇧ $26.14 |
| Genmab (GMAB) | 89.39% | $37.12 | ⇧ $37.65 |
| Verizon (VZ) | 89.23% | $38.03 | ⇧ $39.05 |
| Mondelez International (MDLZ) | 89.22% | $69.6 | ⇧ $69.88 |
| Bio-Techne Corp (TECH) | 89.02% | $71.59 | ⇧ $72.56 |
| Fomento Economico Mexicano S.A.B. de C.V. (FMX) | 88.99% | $93.04 | ⇧ $94.49 |
| Rogers Communication (RCI) | 88.93% | $46.64 | ⇧ $47.48 |
| HCA Holdings (HCA) | 88.86% | $254.76 | ⇧ $259.33 |
| Baxter International (BAX) | 88.85% | $39.87 | ⇧ $40.74 |
| General Mills (GIS) | 88.8% | $84.67 | ⇧ $85.83 |
| Quidel (QDEL) | 88.8% | $87.39 | ⇧ $90.26 |
| argenx SE (ARGX) | 88.77% | $367.15 | ⇧ $380.23 |
| Toyota (TM) | 88.67% | $137.86 | ⇧ $141.57 |
| Berkshire Hathaway (BRK-B) | 88.65% | $302.17 | ⇧ $310.48 |
| Toronto Dominion Bank (TD) | 88.51% | $58.75 | ⇧ $59.98 |
| Atrion (ATRI) | 88.45% | $641 | ⇧ $657.72 |
| Astrazeneca (AZN) | 88.37% | $68.62 | ⇧ $70.24 |
| Martin Marietta Materials (MLM) | 88.34% | $346.39 | ⇧ $357.01 |
| PerkinElmer (PKI) | 88.31% | $128.59 | ⇧ $133.47 |
| Arthur J. Gallagher & Co. (AJG) | 88.25% | $186.54 | ⇧ $191.12 |
| Novartis AG (NVS) | 88.2% | $90.97 | ⇧ $92.05 |
| CVS Health (CVS) | 88.15% | $73.08 | ⇧ $75.2 |
| Danaher Corporation (DHR) | 88.06% | $246.71 | ⇧ $254.64 |
| Novo Nordisk A/S (NVO) | 88.05% | $155.26 | ⇧ $160.68 |
| Celsius Holdings (CELH) | 88.01% | $89.79 | ⇧ $92.73 |
| Pepsico (PEP) | 87.95% | $179.46 | ⇧ $182.77 |
| Aon plc (AON) | 87.87% | $309.13 | ⇧ $318.28 |
1. GlaxoSmithKline (GSK)
Shares of GlaxoSmithKline rose 0.8% in from $34.84 to $35.12 at 19:21 EST on Tuesday, following the last session’s upward trend. NYSE is jumping 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Wave Life Sciences Ltd.; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GlaxoSmithKline’s stock is considered to be overbought (>=80).
More news about GlaxoSmithKline.
2. Visa (V)
Shares of Visa slid 0.19% in from $220.26 to $219.84 at 19:21 EST on Tuesday, after two consecutive sessions in a row of gains. NYSE is jumping 0.37% to $14,949.35, after two successive sessions in a row of gains.
Visa Inc. operates as a payments technology company worldwide. The company operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. It also offers credit, debit, and prepaid card products; tap to pay, tokenization, click to pay; Visa Direct, a real-time payments network; Visa B2B Connect, a multilateral B2B cross-border payments network; Visa Treasury as a Service, a cross-border consumer payments business; and Visa DPS that provides a range of value added services, including fraud mitigation, dispute management, data analytics, campaign management, a suite of digital solutions, and contact center services. Further, the; company provides Cybersource, a payment management platform; and risk and identity solutions, such as Visa Advanced Authorization, Visa Secure, Visa Advanced Identity Score, and Visa Consumer Authentication Service; and Visa Consulting and Analytics, a payments consulting advisory services. It provides its services under the Visa, Visa Electron, Interlink, VPAY, and PLUS brands. The company serves consumers, merchants, financial institutions, and government entities. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.4%, now sitting on 30.19B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 10.6% and 5.6%, respectively.
Sales Growth
Visa’s sales growth is 8.1% for the ongoing quarter and 10.3% for the next.
Volatility
Visa’s last week, last month’s, and last quarter’s current intraday variation average was 0.14%, 0.03%, and 0.81%.
Visa’s highest amplitude of average volatility was 0.63% (last week), 0.94% (last month), and 0.81% (last quarter).
Previous days news about Visa
- Visa (v) makes second bid of $1.4b to acquire Brazilian pismo. According to Zacks on Monday, 27 March, "Shares of Visa have gained 6.3% in the year-to-date period compared with the industry’s 2.9% jump."
More news about Visa.
3. Hasbro (HAS)
Shares of Hasbro slid by a staggering 11.13% in from $56.73 to $50.42 at 19:21 EST on Tuesday, after two successive sessions in a row of gains. NASDAQ is dropping 0.45% to $11,716.08, following the last session’s downward trend.
Hasbro, Inc., together with its subsidiaries, operates as a play and entertainment company. Its Consumer Products segment engages in the sourcing, marketing, and sale of toy and game products. This segment also promotes its brands through the out-licensing of trademarks, characters, and other brand and intellectual property rights to third parties through the sale of branded consumer products, such as toys and apparels. Its toys and games include action figures, arts and crafts and creative play products, fashion and other dolls, play sets, preschool toys, plush products, sports action blasters and accessories, vehicles and toy-related specialty products, games, and other consumer products; and licensed products, such as apparels, publishing products, home goods and electronics, and toy products. The company's Wizards of the Coast and Digital Gaming segment engages in the promotion of its brands through the development of trading card, role-playing, and digital game experiences based on Hasbro and Wizards of the Coast games. Its Entertainment segment engages in the development, acquisition, production, distribution, and sale of world-class entertainment content, including film, scripted and unscripted television, family programming, digital content, and live entertainment. The company sells its products to retailers, distributors, wholesalers, discount stores, drug stores, mail order houses, catalog stores, department stores, and other traditional retailers, as well as ecommerce retailers; and directly to customer through Hasbro PULSE e-commerce website. Hasbro, Inc. was founded in 1923 and is headquartered in Pawtucket, Rhode Island.
Sales Growth
Hasbro’s sales growth is negative 16.7% for the ongoing quarter and negative 8.7% for the next.
Volatility
Hasbro’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.72%, a negative 0.56%, and a positive 1.91%.
Hasbro’s highest amplitude of average volatility was 1.02% (last week), 1.87% (last month), and 1.91% (last quarter).
More news about Hasbro.
4. Match Group (MTCH)
Shares of Match Group dropped 6.66% in from $42.31 to $39.49 at 19:21 EST on Tuesday, after four sequential sessions in a row of gains. NASDAQ is dropping 0.45% to $11,716.08, following the last session’s downward trend.
Match Group, Inc. provides dating products worldwide. The company's portfolio of brands includes Tinder, Match, Meetic, OkCupid, Hinge, Pairs, PlentyOfFish, and OurTime, as well as a various other brands. The company was incorporated in 1986 and is based in Dallas, Texas.
Yearly Top and Bottom Value
Match Group’s stock is valued at $39.49 at 19:21 EST, way under its 52-week high of $114.36 and way higher than its 52-week low of $34.62.
Moving Average
Match Group’s value is way below its 50-day moving average of $44.14 and way under its 200-day moving average of $52.82.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 31.7% and positive 554.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2.5%, now sitting on 3.19B for the twelve trailing months.
More news about Match Group.
5. General Motors (GM)
Shares of General Motors slid by a staggering 14.75% in from $40.09 to $34.18 at 19:21 EST on Tuesday, following the last session’s upward trend. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
General Motors Company designs, builds, and sells trucks, crossovers, cars, and automobile parts; and provide software-enabled services and subscriptions worldwide. The company operates through GM North America, GM International, Cruise, and GM Financial segments. It markets its vehicles primarily under the Buick, Cadillac, Chevrolet, GMC, Baojun, and Wuling brand names. The company also sells trucks, crossovers, cars, and automobile parts through retail dealers, and distributors and dealers, as well as to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers range of after-sale services through dealer network, such as maintenance, light repairs, collision repairs, vehicle accessories, and extended service warranties; and safety and security services for retail and fleet customers, including automatic crash response, emergency services, roadside assistance, crisis assist, stolen vehicle assistance, and turn-by-turn navigation. Further, the company provides connected services comprising mobile applications for owners to remotely control their vehicles and electric vehicle owners to locate charging stations, on-demand vehicle diagnostics, GM Smart Driver, Amazon Alexa in-vehicle voice, Google's Voice Assistant, navigation and app ecosystem, connected navigation, SiriusXM with 360L, and 4G LTE wireless connectivity. Additionally, the company provides automotive financing and insurance services; and software-enabled services and subscriptions. General Motors Company was founded in 1908 and is headquartered in Detroit, Michigan.
Yearly Top and Bottom Value
General Motors’s stock is valued at $34.18 at 19:21 EST, way below its 52-week high of $46.74 and way above its 52-week low of $30.33.
More news about General Motors.
6. Honda (HMC)
Shares of Honda dropped 1.24% in from $26.17 to $25.85 at 19:21 EST on Tuesday, after five sequential sessions in a row of gains. NYSE is jumping 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
Honda Motor Co., Ltd. develops, manufactures, and distributes motorcycles, automobiles, power products, and other products in Japan, North America, Europe, Asia, and internationally. It operates through four segments: Motorcycle Business, Automobile Business, Financial Services Business, and Life Creation and Other Businesses. The Motorcycle Business segment produces motorcycles, including sports, business, and commuter models; and various off-road vehicles, such as all-terrain vehicles and side-by-sides. The Automobile Business segment offers passenger cars, light trucks, and mini vehicles. The Financial Services Business segment provides various financial services, including retail lending and leasing services to customers, as well as wholesale financing services to dealers. The Life Creation and Other Businesses segment manufactures and sells power products, such as general purpose engines, generators, water pumps, lawn mowers, riding mowers, robotic mowers, brush cutters, tillers, snow blowers, outboard marine engines, walking assist devices, and portable battery inverter power sources. This segment also offers HondaJet aircraft. The company also sells spare parts; and provides after-sale services through retail dealers directly, as well as through independent distributors and licensees. Honda Motor Co., Ltd. was founded in 1946 and is headquartered in Tokyo, Japan.
Yearly Top and Bottom Value
Honda’s stock is valued at $25.85 at 19:21 EST, way below its 52-week high of $29.19 and way higher than its 52-week low of $21.44.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Honda’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 15.65T for the twelve trailing months.
More news about Honda.
7. Genmab (GMAB)
Shares of Genmab fell 1.91% in from $37.84 to $37.12 at 19:21 EST on Tuesday, after four consecutive sessions in a row of gains. NASDAQ is dropping 0.45% to $11,716.08, following the last session’s downward trend.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Moving Average
Genmab’s worth is under its 50-day moving average of $37.97 and below its 200-day moving average of $37.59.
More news about Genmab.
8. Verizon (VZ)
Shares of Verizon fell 2% in from $38.81 to $38.03 at 19:21 EST on Tuesday, after five sequential sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
Verizon Communications Inc., through its subsidiaries, provides communications, technology, information, and entertainment products and services to consumers, businesses, and governmental entities worldwide. It operates in two segments, Verizon Consumer Group (Consumer) and Verizon Business Group (Business). The Consumer segment provides wireless services across the wireless networks in the United States under the Verizon and TracFone brands and through wholesale and other arrangements; and fixed wireless access (FWA) broadband through its wireless networks. It also offers wireline services in the Mid-Atlantic and Northeastern United States, as well as Washington D.C. through its fiber-optic network, Verizon Fios product portfolio, and a copper-based network. The Business segment provides wireless and wireline communications services and products, including data, video, conferencing, corporate networking, security and managed network, local and long-distance voice, network access, and various IoT services and products, as well as FWA broadband through its wireless networks. The company was formerly known as Bell Atlantic Corporation and changed its name to Verizon Communications Inc. in June 2000. Verizon Communications Inc. was incorporated in 1983 and is headquartered in New York, New York.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 11.9% and a negative 9.9%, respectively.
More news about Verizon.
9. Mondelez International (MDLZ)
Shares of Mondelez International rose 6% in from $65.66 to $69.60 at 19:21 EST on Tuesday, after two successive sessions in a row of gains. NASDAQ is sliding 0.45% to $11,716.08, following the last session’s downward trend.
Mondelez International, Inc., through its subsidiaries, manufactures, markets, and sells snack food and beverage products in the Latin America, North America, Asia, the Middle East, Africa, and Europe. It provides biscuits and baked snacks, including cookies, crackers, salted snacks, snack bars, and cakes and pastries; chocolates; and gums and candies, as well as various cheese and grocery, and powdered beverage products. The company's brand portfolio includes Oreo, Ritz, LU, CLIF Bar, and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka, and Toblerone chocolate. It serves supermarket chains, wholesalers, supercenters, club stores, mass merchandisers, distributors, convenience stores, gasoline stations, drug stores, value stores, and other retail food outlets through direct store delivery, company-owned and satellite warehouses, third party distributors, and other facilities, as well as through independent sales offices and agents. The company was formerly known as Kraft Foods Inc. and changed its name to Mondelez International, Inc. in October 2012. Mondelez International, Inc. was incorporated in 2000 and is headquartered in Chicago, Illinois.
Yearly Top and Bottom Value
Mondelez International’s stock is valued at $69.60 at 19:21 EST, higher than its 52-week high of $69.10.
Moving Average
Mondelez International’s worth is above its 50-day moving average of $65.78 and higher than its 200-day moving average of $63.44.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 3.6% and positive 4.5% for the next.
More news about Mondelez International.
10. Bio-Techne Corp (TECH)
Shares of Bio-Techne Corp slid 1.48% in from $72.67 to $71.59 at 19:21 EST on Tuesday, after two consecutive sessions in a row of gains. NASDAQ is sliding 0.45% to $11,716.08, following the last session’s downward trend.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Sales Growth
Bio-Techne Corp’s sales growth is 2.1% for the ongoing quarter and 9.7% for the next.
Volatility
Bio-Techne Corp’s last week, last month’s, and last quarter’s current intraday variation average was 0.28%, 0.11%, and 1.57%.
Bio-Techne Corp’s highest amplitude of average volatility was 0.75% (last week), 1.44% (last month), and 1.57% (last quarter).
More news about Bio-Techne Corp.
11. Fomento Economico Mexicano S.A.B. de C.V. (FMX)
Shares of Fomento Economico Mexicano S.A.B. de C.V. slid 0.3% in from $93.32 to $93.04 at 19:21 EST on Tuesday, after four successive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
Fomento Económico Mexicano, S.A.B. de C.V., through its subsidiaries, operates as a bottler of Coca-Cola trademark beverages. The company produces, markets, and distributes Coca-Cola trademark beverages in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Venezuela, Brazil, Argentina, and Uruguay. It also operates small-box retail chain stores in Mexico, Colombia, Peru, Chile, and Brazil under the OXXO name; retail service stations for fuels, motor oils, lubricants, and car care products under the OXXO GAS name in Mexico; and drugstores in Chile, Colombia, Ecuador, and Mexico under the Cruz Verde, Fybeca, SanaSana, YZA, La Moderna, and Farmacon names. In addition, the company is involved in the production and distribution of chillers, commercial refrigeration equipment, plastic boxes, food processing, and preservation and weighing equipment; and provision of logistic transportation, distribution and maintenance, point-of-sale refrigeration, and plastics solutions, as well as distribution platform for cleaning products and consumables. As of December 31, 2021, it operated 20,431 OXXO stores; 3,652 drugstores; and 567 OXXO GAS service stations. Fomento Económico Mexicano, S.A.B. de C.V. was founded in 1890 and is based in Monterrey, Mexico.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Fomento Economico Mexicano S.A.B. de C.V.’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 639.24B for the twelve trailing months.
Sales Growth
Fomento Economico Mexicano S.A.B. de C.V.’s sales growth is 22.9% for the current quarter and 20.4% for the next.
More news about Fomento Economico Mexicano S.A.B. de C.V..
12. Rogers Communication (RCI)
Shares of Rogers Communication fell 2.74% in from $47.95 to $46.64 at 19:21 EST on Tuesday, after five successive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
Rogers Communications Inc. operates as a communications and media company in Canada. It operates through three segments: Wireless, Cable, and Media. The company offers mobile Internet access, wireless voice and enhanced voice, device and accessory financing, wireless home phone, device protection, e-mail, global voice and data roaming, bridging landline, machine-to-machine and Internet of Things solutions, and advanced wireless solutions for businesses, as well as device delivery services; and postpaid and prepaid services under the Rogers, Fido, and chatr brands to approximately 11.3 million subscribers. It also provides Internet and WiFi services; smart home monitoring services, such as monitoring, security, automation, energy efficiency, and smart control through a smartphone app. In addition, the company offers local and network TV; on-demand television; cloud-based digital video recorders; voice-activated remote controls, and integrated apps; personal video recorders; linear and time-shifted programming; digital specialty channels; 4K television programming; and televised content on smartphones, tablets, and personal computers, as well as operates Ignite TV and Ignite TV app. Further, it provides residential and small business local telephony services; calling features, such as voicemail, call waiting, and long distance; voice, data networking, Internet protocol, and Ethernet services; private networking, Internet, IP voice, and cloud solutions; optical wave and multi-protocol label switching services; IT and network technologies; and cable access network services. The company also owns Toronto Blue Jays and the Rogers Centre event venue; and operates Sportsnet ONE, Sportsnet 360, Sportsnet World, Citytv, OMNI, FX (Canada), FXX (Canada), and OLN television networks, as well as 55 AM and FM radio stations. The company was founded in 1960 and is headquartered in Toronto, Canada.
Volatility
Rogers Communication’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.18%, a negative 0.50%, and a positive 0.98%.
Rogers Communication’s highest amplitude of average volatility was 0.39% (last week), 1.17% (last month), and 0.98% (last quarter).
Moving Average
Rogers Communication’s value is under its 50-day moving average of $47.86 and above its 200-day moving average of $45.21.
More news about Rogers Communication.
13. HCA Holdings (HCA)
Shares of HCA Holdings rose 2.73% in from $247.99 to $254.76 at 19:21 EST on Tuesday, after two consecutive sessions in a row of gains. NYSE is jumping 0.37% to $14,949.35, after two sequential sessions in a row of gains.
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Moving Average
HCA Holdings’s value is higher than its 50-day moving average of $254.20 and way higher than its 200-day moving average of $221.12.
Volatility
HCA Holdings’s last week, last month’s, and last quarter’s current intraday variation average was 0.09%, 0.38%, and 1.12%.
HCA Holdings’s highest amplitude of average volatility was 0.51% (last week), 1.30% (last month), and 1.12% (last quarter).
Sales Growth
HCA Holdings’s sales growth is 2.4% for the current quarter and 4.5% for the next.
More news about HCA Holdings.
14. Baxter International (BAX)
Shares of Baxter International slid 0.1% in from $39.91 to $39.87 at 19:21 EST on Tuesday, after two sequential sessions in a row of gains. NYSE is jumping 0.37% to $14,949.35, after two successive sessions in a row of gains.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 28% and a negative 13.8%, respectively.
Moving Average
Baxter International’s value is under its 50-day moving average of $41.74 and way below its 200-day moving average of $53.69.
More news about Baxter International.
15. General Mills (GIS)
Shares of General Mills jumped 4.44% in from $81.07 to $84.67 at 19:21 EST on Tuesday, after five consecutive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two successive sessions in a row of gains.
General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, General Mills’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
General Mills’s stock is valued at $84.67 at 19:21 EST, below its 52-week high of $88.34 and way above its 52-week low of $64.94.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 7.1% and a drop 8% for the next.
Sales Growth
General Mills’s sales growth is 7.9% for the current quarter and 3.2% for the next.
More news about General Mills.
16. Quidel (QDEL)
Shares of Quidel dropped 0.51% in from $87.84 to $87.39 at 19:21 EST on Tuesday, after two sequential sessions in a row of gains. NASDAQ is dropping 0.45% to $11,716.08, following the last session’s downward trend.
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Sales Growth
Quidel’s sales growth is 22.4% for the current quarter and negative 27.6% for the next.
More news about Quidel.
17. argenx SE (ARGX)
Shares of argenx SE slid 0.88% in from $370.41 to $367.15 at 19:21 EST on Tuesday, after four successive sessions in a row of gains. NASDAQ is sliding 0.45% to $11,716.08, following the last session’s downward trend.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Moving Average
argenx SE’s worth is under its 50-day moving average of $368.93 and under its 200-day moving average of $370.00.
Yearly Top and Bottom Value
argenx SE’s stock is valued at $367.15 at 19:21 EST, under its 52-week high of $407.93 and way higher than its 52-week low of $267.35.
More news about argenx SE.
18. Toyota (TM)
Shares of Toyota rose 1.15% in from $136.29 to $137.86 at 19:21 EST on Tuesday, after five consecutive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
Toyota Motor Corporation designs, manufactures, assembles, and sells passenger vehicles, minivans and commercial vehicles, and related parts and accessories. It operates in Automotive, Financial Services, and All Other segments. The company offers hybrid cars under the Prius name, fuel cell vehicles under the MIRAI name; and conventional engine vehicles, including subcompact and compact cars under the Corolla and Raize names. It also provides mini-vehicles, passenger vehicles, commercial vehicles, and auto parts under the Toyota name; mid-size cars; luxury cars; sports cars under the GR Yaris, Corolla Sport, Corolla Cross, and Supra names; and recreational and sport-utility vehicles under the Highlander name. In addition, the company offers pickup trucks under the Tacoma name; minivans; and trucks and buses. Further, it provides financial services, such as retail financing and leasing, wholesale financing, insurance, and credit cards; and designs, manufactures, and sells prefabricated housing. Additionally, the company operates GAZOO.com, a web portal for automobile information. It operates in Japan, North America, Europe, Asia, Central and South America, Oceania, Africa, and the Middle East. The company was founded in 1933 and is headquartered in Toyota, Japan.
Moving Average
Toyota’s value is under its 50-day moving average of $141.40 and below its 200-day moving average of $146.66.
More news about Toyota.
19. Berkshire Hathaway (BRK-B)
Shares of Berkshire Hathaway slid 0.83% in from $304.7 to $302.17 at 19:21 EST on Tuesday, after two successive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
: occidental petroleum stock surges after upgrade at TD cowen, which includes large investment by warren buffett’s Berkshire Hathaway as a reason to be bullishHe listed a number of reasons for his bullishness, such as superior exposure to crude oil pricing, capital structure shifts, a favorable free cash flow yield, well productivity and captive buying support from Warren Buffett’s Berkshire Hathaway Inc. , which has been steadily increasing its stake in the company since early 2022 to be Occidental’s largest shareholder.
Berkshire Hathaway Inc., through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide. It provides property, casualty, life, accident, and health insurance and reinsurance; and operates railroad systems in North America. The company also generates, transmits, stores, and distributes electricity from natural gas, coal, wind, solar, hydroelectric, nuclear, and geothermal sources; operates natural gas distribution and storage facilities, interstate pipelines, liquefied natural gas facilities, and compressor and meter stations; and holds interest in coal mining assets. In addition, the company manufactures boxed chocolates and other confectionery products; specialty chemicals, metal cutting tools, and components for aerospace and power generation applications; flooring products; insulation, roofing, and engineered products; building and engineered components; paints and coatings; and bricks and masonry products, as well as offers manufactured and site-built home construction, and related lending and financial services. Further, it provides recreational vehicles, apparel products, jewelry, and custom picture framing products, as well as alkaline batteries; castings, forgings, fasteners/fastener systems, and aerostructures; and seamless pipes, fittings, downhole casing and tubing, and mill forms. Additionally, the company distributes televisions and information; franchises and services quick service restaurants; distributes electronic components; and offers logistics services, grocery and foodservice distribution services, and professional aviation training and shared aircraft ownership programs. It also retails automobiles; furniture, bedding, and accessories; household appliances, electronics, and computers; jewelry, watches, crystal, china, stemware, flatware, gifts, and collectibles; kitchenware; and motorcycle apparel and equipment. The company was incorporated in 1998 and is headquartered in Omaha, Nebraska.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9%, now sitting on 295.72B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Berkshire Hathaway’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
Berkshire Hathaway’s stock is valued at $302.17 at 19:21 EST, way below its 52-week high of $362.10 and way above its 52-week low of $259.85.
Sales Growth
Berkshire Hathaway’s sales growth is 9.5% for the ongoing quarter and 12.6% for the next.
More news about Berkshire Hathaway.
20. Toronto Dominion Bank (TD)
Shares of Toronto Dominion Bank slid by a staggering 13.55% in from $67.96 to $58.75 at 19:21 EST on Tuesday, after four sequential sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
The Toronto-Dominion Bank, together with its subsidiaries, provides various financial products and services in Canada, the United States, and internationally. It operates through Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, and Wholesale Banking segments. The company offers personal deposits, such as checking, savings, and investment products; financing, investment, cash management, international trade, and day-to-day banking services to businesses; and financing options to customers at point of sale for automotive and recreational vehicle purchases. It also provides credit cards and payments; real estate secured lending, auto finance, and consumer lending services; point-of-sale payment solutions for large and small businesses; wealth and asset management products, and advice to retail and institutional clients through direct investing, advice-based, and asset management businesses; property and casualty insurance; and life and health insurance products, as well as reinsurance products. The company also provides capital markets, and corporate and investment banking products and services, including underwriting and distribution of new debt and equity issues; advice on strategic acquisitions and divestitures; and trading, funding, and investment services to corporations, governments, and institutions. It offers its products and services under the TD Bank and America's Most Convenient Bank brand names. The company operates through a network of 1,060 branches and 3,401 automated teller machines (ATMs) in Canada, and 1,160 stores and 2,693 ATMs in the United States, as well as offers telephone, digital, and mobile banking services. The Toronto-Dominion Bank was founded in 1855 and is headquartered in Toronto, Canada.
More news about Toronto Dominion Bank.
21. Atrion (ATRI)
Shares of Atrion fell 6.52% in from $685.71 to $641.00 at 19:21 EST on Tuesday, following the last session’s downward trend. NASDAQ is sliding 0.45% to $11,716.08, following the last session’s downward trend.
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Atrion’s stock is considered to be overbought (>=80).
Moving Average
Atrion’s worth is under its 50-day moving average of $647.40 and above its 200-day moving average of $621.28.
Volatility
Atrion’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.08%, a positive 0.43%, and a positive 2.23%.
Atrion’s highest amplitude of average volatility was 1.30% (last week), 2.11% (last month), and 2.23% (last quarter).
Yearly Top and Bottom Value
Atrion’s stock is valued at $641.00 at 19:21 EST, way under its 52-week high of $766.72 and way higher than its 52-week low of $534.99.
More news about Atrion.
22. Astrazeneca (AZN)
Shares of Astrazeneca jumped 2.8% in from $66.75 to $68.62 at 19:21 EST on Tuesday, after three consecutive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Volatility
Astrazeneca’s last week, last month’s, and last quarter’s current intraday variation average was 0.76%, 0.30%, and 1.04%.
Astrazeneca’s highest amplitude of average volatility was 0.85% (last week), 0.68% (last month), and 1.04% (last quarter).
Yearly Top and Bottom Value
Astrazeneca’s stock is valued at $68.62 at 19:21 EST, below its 52-week high of $72.12 and way higher than its 52-week low of $52.65.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Astrazeneca’s stock is considered to be oversold (<=20).
More news about Astrazeneca.
23. Martin Marietta Materials (MLM)
Shares of Martin Marietta Materials slid 3.88% in from $360.37 to $346.39 at 19:21 EST on Tuesday, after five sequential sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
Martin Marietta Materials, Inc., a natural resource-based building materials company, supplies aggregates and heavy-side building materials to the construction industry in the United States and internationally. It offers crushed stone, sand, and gravel products; ready mixed concrete and asphalt; paving products and services; and Portland and specialty cement for use in the infrastructure projects, and nonresidential and residential construction markets, as well as in the railroad, agricultural, utility, and environmental industries. The company also produces magnesia-based chemicals products that are used in industrial, agricultural, and environmental applications; and dolomitic lime primarily to customers for steel production and soil stabilization. Its chemical products are used in flame retardants, wastewater treatment, pulp and paper production, and other environmental applications. The company was founded in 1939 and is headquartered in Raleigh, North Carolina.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 2.5% and positive 117.9% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Martin Marietta Materials’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
Martin Marietta Materials’s stock is valued at $346.39 at 19:21 EST, way below its 52-week high of $406.85 and way above its 52-week low of $284.99.
Moving Average
Martin Marietta Materials’s worth is under its 50-day moving average of $351.78 and above its 200-day moving average of $340.70.
More news about Martin Marietta Materials.
24. PerkinElmer (PKI)
Shares of PerkinElmer jumped 4.12% in from $123.5 to $128.59 at 19:21 EST on Tuesday, after five consecutive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Sales Growth
PerkinElmer’s sales growth is negative 24.1% for the present quarter and negative 26.7% for the next.
More news about PerkinElmer.
25. Arthur J. Gallagher & Co. (AJG)
Shares of Arthur J. Gallagher & Co. jumped 0.78% in from $185.1 to $186.54 at 19:21 EST on Tuesday, after five successive sessions in a row of gains. NYSE is jumping 0.37% to $14,949.35, after two successive sessions in a row of gains.
Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance brokerage, consulting, third-party claims settlement, and administration services in the United States, Australia, Bermuda, Canada, the Caribbean, New Zealand, India, and the United Kingdom. It operates through Brokerage and Risk Management segments. The Brokerage segment consists of retail and wholesale insurance brokerage operations; assists retail brokers and other non-affiliated brokers in the placement of specialized and hard-to-place insurance; acts as a brokerage wholesaler, managing general agent, and managing general underwriter for distributing specialized insurance coverage's to underwriting enterprises. This segment also performs activities, including marketing, underwriting, issuing policies, collecting premiums, appointing and supervising other agents, paying claims, and negotiating reinsurance; and offers brokerage and consulting services to businesses and organizations, including commercial, not-for-profit, and public entities, as well as individuals in the areas of insurance placement, risk of loss management, and management of employer sponsored benefit programs. The Risk Management segment provides contract claim settlement and administration services to enterprises and public entities; and claims management, loss control consulting, and insurance property appraisal services. The company offers its services through a network of correspondent insurance brokers and consultants. It serves commercial, industrial, public, religious, and not-for-profit entities. The company was incorporated in 1927 and is headquartered in Rolling Meadows, Illinois.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 7.5% and 14.7%, respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Arthur J. Gallagher & Co.’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 8.27B for the twelve trailing months.
More news about Arthur J. Gallagher & Co..
26. Novartis AG (NVS)
Shares of Novartis AG rose 6.31% in from $85.57 to $90.97 at 19:21 EST on Tuesday, after five sequential sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Sales Growth
Novartis AG’s sales growth is 1.3% for the present quarter and 1.8% for the next.
Yearly Top and Bottom Value
Novartis AG’s stock is valued at $90.97 at 19:21 EST, below its 52-week high of $94.26 and way above its 52-week low of $74.09.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.2%, now sitting on 51.83B for the twelve trailing months.
Moving Average
Novartis AG’s value is above its 50-day moving average of $86.43 and above its 200-day moving average of $84.53.
More news about Novartis AG.
27. CVS Health (CVS)
Shares of CVS Health slid by a staggering 16% in from $87 to $73.08 at 19:21 EST on Tuesday, after two successive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two successive sessions in a row of gains.
CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
Yearly Top and Bottom Value
CVS Health’s stock is valued at $73.08 at 19:21 EST, way below its 52-week high of $108.25 and higher than its 52-week low of $72.11.
Sales Growth
CVS Health’s sales growth is 3.8% for the present quarter and 2.3% for the next.
Volatility
CVS Health’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.30%, a negative 0.79%, and a positive 1.08%.
CVS Health’s highest amplitude of average volatility was 1.13% (last week), 1.39% (last month), and 1.08% (last quarter).
More news about CVS Health.
28. Danaher Corporation (DHR)
Shares of Danaher Corporation fell 1.41% in from $250.24 to $246.71 at 19:21 EST on Tuesday, after two sequential sessions in a row of losses. NYSE is jumping 0.37% to $14,949.35, after two consecutive sessions in a row of gains.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Moving Average
Danaher Corporation’s value is under its 50-day moving average of $256.66 and under its 200-day moving average of $264.07.
More news about Danaher Corporation.
29. Novo Nordisk A/S (NVO)
Shares of Novo Nordisk A/S jumped 8.1% in from $143.63 to $155.26 at 19:21 EST on Tuesday, after five successive sessions in a row of gains. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Moving Average
Novo Nordisk A/S’s value is way higher than its 50-day moving average of $141.13 and way higher than its 200-day moving average of $120.01.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.5%, now sitting on 176.95B for the twelve trailing months.
More news about Novo Nordisk A/S.
30. Celsius Holdings (CELH)
Shares of Celsius Holdings fell 0.88% in from $90.59 to $89.79 at 19:21 EST on Tuesday, after three successive sessions in a row of gains. NASDAQ is falling 0.45% to $11,716.08, following the last session’s downward trend.
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in North America, Europe, Asia, and internationally. It offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. The company also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened. It distributes its products through direct-to-store delivery distributors and direct to retailers, including supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Moving Average
Celsius Holdings’s worth is below its 50-day moving average of $94.11 and under its 200-day moving average of $92.82.
Yearly Top and Bottom Value
Celsius Holdings’s stock is valued at $89.79 at 19:21 EST, way under its 52-week high of $122.24 and way higher than its 52-week low of $38.31.
Sales Growth
Celsius Holdings’s sales growth is 71.8% for the ongoing quarter and 61.9% for the next.
More news about Celsius Holdings.
31. Pepsico (PEP)
Shares of Pepsico rose 1.93% in from $176.06 to $179.46 at 19:21 EST on Tuesday, after two consecutive sessions in a row of gains. NASDAQ is dropping 0.45% to $11,716.08, following the last session’s downward trend.
PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.
Sales Growth
Pepsico’s sales growth is 4.3% for the ongoing quarter and 4% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Pepsico’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 83.64B for the twelve trailing months.
More news about Pepsico.
32. Aon plc (AON)
Shares of Aon plc jumped 2.2% in from $302.48 to $309.13 at 19:21 EST on Tuesday, following the last session’s downward trend. NYSE is rising 0.37% to $14,949.35, after two sequential sessions in a row of gains.
Aon plc, a professional services firm, provides advice and solutions to clients focused on risk, retirement, and health worldwide. It offers commercial risk solutions, including retail brokerage, cyber, and global risk consulting solutions, as well as acts as a captives management; and health solutions, such as health and benefits brokerages, and health care exchanges. The company also provides treaty and facultative reinsurance, as well as insurance-linked securities, capital raising, strategic advice, restructuring, and mergers and acquisitions services; and corporate finance advisory services and capital markets solutions products. In addition, it offers strategic design consulting services on their retirement programs, actuarial services, and risk management services; advice services on developing and maintaining investment programs across a range of plan types, including defined benefit plans, defined contribution plans, endowments, and foundations for public and private companies, and other institutions; and advice and solutions that help clients in risk, health, and wealth through commercial risk, reinsurance, health, and wealth solutions. Further, the company offers CoverWallet; Affinity; Aon Inpoint; CoverWallet; and ReView services. Aon plc was founded in 1919 and is headquartered in Dublin, Ireland.
More news about Aon plc.
